Donald McDonnell

Overview

The research in our group is focused on the development and application of mechanism based approaches to identify novel therapeutics for use in the treatment and prevention of hormonally responsive cancers. Specifically we are interested in the pharmaceutical exploitation of the estrogen and androgen receptors as therapeutic targets in breast and prostate cancers and in defining how these receptors influence the pathogenesis of these diseases. These efforts have led to the discovery of several drugs that are currently being evaluated in the clinic as cancer therapeutics, and to the identification of potential biomarkers and predictors of response that can help to target the use of these new drugs. Most recently we have explored approaches to treat triple negative breast cancer and have identified an important pathway that links obesity/dyslipidemia and cancer risk.

Positions

Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine in the School of Medicine

2002 School of Medicine

Professor of Pharmacology and Cancer Biology in the School of Medicine

2000 School of Medicine

Professor in Medicine in the School of Medicine

2002 School of Medicine

Professor of Cell Biology in the School of Medicine

2022 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

1994 School of Medicine

Education

Ph.D. 1988

1988 Baylor College of Medicine

Publications, Grants & Awards

Grants (85)
Awards (22)
Academics Articles (321)
Conference Pages (30)
Book Sections (2)

Offices & Contact

C238a Lev Sci Res Ctr
Durham, NC
27708

Duke Box 3813
Durham, NC
27710